Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC28A1 | O00337 | 1/20 | 0.49 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.49 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.49 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.49 |
| ▸ | P2RY14 | Q15391 | 5/20 | 0.41 |
| ▸ | P2RY2 | P41231 | 4/20 | 0.36 |
| ▸ | P2RY6 | Q15077 | 7/20 | 0.36 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.35 |
| ▸ | PYGB | P11216 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8941498 | 1.00 | SLC28A1 (0.49) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL28250490 | 0.91 | SLC28A1 (0.48) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL121731 | 0.90 | SLC28A1 (0.47) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL4849439 | 0.90 | SLC28A1 (0.47) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL9644061 | 0.90 | SLC28A1 (0.47) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL6389231 | 0.90 | SLC28A1 (0.47) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| Uridine SCHEMBL29084593 | 0.88 | SLC28A1 (0.71) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL6879975 | 0.88 | SLC28A1 (0.45) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL17371751 | 0.88 | SLC28A1 (0.45) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL18660236 | 0.88 | SLC28A1 (0.45) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025081064-A2 | THERMOPHILIC DEAMINASE AND METHODS FOR IDENTIFYING MODIFIED CYTOSINE | ILLUMINA, INC. (US) | 2025-04-17 | — | — | WO | claimed |
| US-20250115953-A1 | Methylcytosine-Selective Deaminases and Uses Thereof | NEW ENGLAND BIOLABS, INC. (US) | 2025-04-10 | — | — | US | claimed |
| JP-4651942-B2 | — | — | 2011-03-16 | — | — | JP | claimed |
| EP-1569658-A4 | TREATMENT OF EBV AND KHSV INFECTION AND ASSOCIATED ABNORMAL CELLULAR PROLIFERATION | PHARMASSETT LTD (BB) | 2007-05-30 | — | — | EP | claimed |
| JP-2005528334-A | — | — | 2005-09-22 | — | — | JP | claimed |
| EP-1569658-A2 | TREATMENT OF EBV AND KHSV INFECTION AND ASSOCIATED ABNORMAL CELLULAR PROLIFERATION | Pharmassett Ltd. (BB) | 2005-09-07 | — | — | EP | claimed |
| WO-2003053360-A2 | TREATMENT OF EBV AND KHSV INFECTION AND ASSOCIATED ABNORMAL CELLULAR PROLIFERATION | PHARMASSETT LTD. (BB) | 2003-07-03 | — | — | WO | claimed |
| EP-4665405-A1 | DNA COMPOSITIONS COMPRISING MODIFIED URACIL | Flagship Pioneering Innovations VII, LLC (US) | 2025-12-24 | — | — | EP | disclosed |
| EP-4619531-A1 | SELF-REPLICATING RNA AND USES THEREOF | Trustees of Boston University (US) | 2025-09-24 | — | — | EP | disclosed |
| US-20250270299-A1 | METHODS OF USING COMPOSITIONS COMPRISING SBI DOMAINS | HELIX NANOTECHNOLOGIES INC | 2025-08-28 | — | — | US | disclosed |
| WO-2025081064-A2 | THERMOPHILIC DEAMINASE AND METHODS FOR IDENTIFYING MODIFIED CYTOSINE | ILLUMINA, INC. (US) | 2025-04-17 | — | — | WO | disclosed |
| US-20250115953-A1 | Methylcytosine-Selective Deaminases and Uses Thereof | NEW ENGLAND BIOLABS, INC. (US) | 2025-04-10 | — | — | US | disclosed |
| US-20250115953-A1 | Methylcytosine-Selective Deaminases and Uses Thereof | NEW ENGLAND BIOLABS, INC. (US) | 2025-04-10 | — | — | US | disclosed |
| WO-2021048235-A1 | TREATMENT OF HR DEFICIENT CANCER | THE FRANCIS CRICK INSTITUTE LIMITED (GB) | 2021-03-18 | — | — | WO | disclosed |
| CN-109477102-A | Nucleic acid product and its method of administration | 菲克特生物科学股份有限公司 | 2019-03-15 | — | — | CN | disclosed |
| CN-108707175-A | The novel 2 '-nitrine uridine of one kind and its synthetic method | 南京百芙利科技有限责任公司 | 2018-10-26 | — | — | CN | disclosed |
| US-20030219805-A1 | Detection of alternative and aberrant mRNA splicing | UNIVERSITY OF MARYLAND BIOTECHNOLOGY INSTITUTE | 2003-11-27 | — | — | US | disclosed |
| EP-0792146-A1 | INACTIVATION OF PATHOGENS USING HYDROXYMETHYLAMINES | HEMASURE, INC. (US) | 1997-09-03 | — | — | EP | disclosed |
| WO-1997002028-A1 | INACTIVATION OF PATHOGENS USING HYDROXYMETHYLAMINES | HEMASURE, INC. (US) | 1997-01-23 | — | — | WO | disclosed |
| EP-0554274-A1 | NUCLEOSIDE DERIVATIVES | Medivir Aktiebolag (SE) | 1993-08-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250270299-A1 | METHODS OF USING COMPOSITIONS COMPRISING SBI DOMAINS | C1QBP, SSB, SARNP | SLC28A1 991/4885SLC28A2 1151/4885SLC29A1 949/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.